Bortezomib will enhance the degree or outcome of flibanserin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Improved flibanserin adverse consequences may possibly happen if coadministered with many weak CYP3A4 inhibitors. Other consequences, for instance a pores and skin rash, will not be really serious but may trigger concern. Some https://kirstenx111mxi4.targetblogs.com/profile